🔎 Trials Near Me

Utama › Limfoma Folikular › Kansas

Kajian klinikal Limfoma Folikular di Kansas

7 kajian untuk Limfoma Folikular sedang mencari peserta di lokasi di Kansas.

Bandar di Kansas

Teks kajian rasmi (Bahasa Inggeris)

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  • University of Kansas Cancer Center, Kansas City
  • Lawrence Memorial Hospital, Lawrence
  • University of Kansas Cancer Center-Overland Park, Overland Park
  • dan 2 lagi
Mengambil pesertaFasa 3
Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07215910

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • University of Kansas Cancer Center, Kansas City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07101328

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Hospital-Westwood Cancer Center, Westwood
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06860594

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • University of Kansas Medical Center, Kansas City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT05303519

SynKIR-310 for Relapsed/Refractory B-NHL

  • The University of Kansas Cancer Center, Fairway
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Apr 2026 · NCT06544265

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

  • University of Kansas, Westwood
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Nov 2025 · NCT05643742

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.